Quinine as a multidrug resistance inhibitor: A phase 3 multicentric randomized study in adult de novo acute myelogenous leukemia

Blood

Volumn 102, Issue 4, 2003, Pages 1202-1210

  Solary, Eric ^b   Drenou, Bernard ^c   Campos, Lydia ^c   De Crémoux, Patricia ^c   Mugneret, Francine ^c   Moreau, Philippe ^c   Lioure, Bruno ^c   Falkenrodt, Annie ^c   Witz, Brigitte ^c   Bernard, Marc ^c   Hunault Berger, Mathilde ^c   Delain, Martine ^c   Fernandes, José ^c   Mounier, Christiane ^c   Guilhot, François ^c   Garnache, Francine ^c   Berthou, Christian ^c   Kara Slimane, Fawzi ^c   Harousseau, Jean Luc ^a  

^a HÔTEL DIEU   (France)

^b HÔPITAL DU BOCAGE   (France)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; GLYCOPROTEIN P; IDARUBICIN; MITOXANTRONE; MULTIDRUG RESISTANCE INHIBITOR; QUINIMAX; RHODAMINE 123; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; BONE MARROW EXAMINATION; BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; EFFUSION; FEMALE; HLA MATCHING; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; SURVIVAL TIME; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0043240289     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-11-3419     Document Type: Article

References (68)

1. Stone RM, Mayer RJ. Treatment of the newly diagnosed adult with de novo acute myeloid leukemia. Hematol Oncol Clin North Am. 1993;7:47-64.
2. Estey EH. Therapeutic options for acute myelogenous leukemia. Cancer. 2001;92:1059-1073.
3. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol. 1999;39:361-398.
4. Roninson IB, Chin JE, Choi KG, et al. Isolation of human mdr DNA sequences amplified in multidrug-resistant KB carcinoma cells. Proc Natl Acad Sci U S A. 1986;83:4538-4542.
5. Gottesman MM, Pastan I, Ambudkar SV. P-glycoprotein and multidrug resistance. Curr Opin Genet Dev. 1996;6:610-617.
6. Schinkel AH, Smit JJ, van Tellingen O, et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell. 1994; 77:491-502.
7. Chaudhary PM, Roninson IB. Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell. 1991;66:85-94.
8. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer. 2002;2:48-58.
9. Johnstone RW, Cretney E, Smyth MJ. P-glycoprotein protects leukemia cells against caspase-dependent, but not caspase-independent, cell death. Blood. 1999;93:1075-1085.
10. Marie JP, Zittoun R, Sikic BI. Multidrug resistance (mdr1) gene expression in adult acute leukemias: correlations with treatment outcome and in vitro drug sensitivity. Blood. 1991;78:586-592.
11. Pirker R, Wallner J, Geissler K, et al. MDR1 gene expression and treatment outcome in acute myeloid leukemia. J Natl Cancer Inst. 1991;83:708-712.
12. Campos L, Guyotat D, Archimbaud E, et al. Clinical significance of multidrug resistance P-glyco protein expression on acute nonlymphoblastic leukemia cells at diagnosis. Blood. 1992;79:473-476.
13. Del Poeta G, Stasi R, Aronica G, et al. Clinical relevance of P-glycoprotein expression in de novo acute myeloid leukemia. Blood. 1996;87: 1997-2004.
14. Legrand O, Simonin G, Perrot JY, Zittoun R, Marie JP. Pgp and MRP activities using calcein-AM are prognostic factors in adult acute myeloid leukemia patients. Blood. 1998;91:4480-4488.
15. Zamora JM, Pearce HL, Beck WT. Physical-chemical properties shared by compounds that modulate multidrug resistance in human leukemic cells. Mol Pharmacol. 1988;33:454-462.
16. Sikic BI, Fisher GA, Lum BL, Halsey J, Beketic-Oreskovic L, Chen G. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein. Cancer Chemother Pharmacol. 1997; 40(suppl):S13-S19.
17. Fisher GA, Lum BL, Hausdorff J, Sikic BI. Pharmacological considerations in the modulation of multidrug resistance. Eur J Cancer. 1996;32: 1082-1088.
18. Pennock GD, Dalton WS, Roeske WR, et al. Systemic toxic effects associated with high-dose verapamil infusion and chemotherapy administration. J Natl Cancer Inst. 1991;83:105-110.
19. Chauffert B, Pelletier H, Corda C, et al. Potential usefulness of quinine for the circumvention of the anthracycline resistance in clinical practice. Brit J Cancer. 1990;62:395-397.
20. Solary E, Velay I, Chauffert B, et al. Sufficient levels of quinine in the serum circumvent the multidrug resistance of the human leukemic cell line K562/ADM. Cancer. 1991;68:1714-1719.
21. Solary E, Caillot D, Chauffert B, et al. Feasibility of using quinine, a potential multidrug resistance-reversing agent, in combination with mitoxantrone and cytarabine for the treatment of acute leukemia. J Clin Oncol. 1992;10:1730-1736.
22. Solary E, Witz F, Caillot D, et al. Combination of quinine as a potential reversing agent with mitoxantrone and cytarabine for the treatment of acute leukemias: a randomized multicentric study. Blood. 1996;88:1198-1205.
23. Wattel E, Solary E, Hecquet B, et al. Quinine improves the results of intensive chemotherapy in myelodysplastic syndromes expressing P glycoprotein: results of a randomized study. Br J Haematol. 1998;102:1015-1024.
24. Shtil AA. Emergence of multidrug resistance in leukemia cells during chemotherapy: mechanisms and prevention. J Hematother Stem Cell Res. 2002;11:231-241.
25. Futscher BW, Foley NE, Gleason-Guzman MC, Meltzer PS, Sullivan DM, Dalton WS. Verapamil suppresses the emergence of P-glycoprotein-mediated multi-drug resistance. Int J Cancer. 1996;66:520-525.
26. Harousseau JL, Witz B, Lioure B, et al. Granulocyte colony-stimulating factor after intensive consolidation chemotherapy in acute myeloid leukemia: results of a randomized trial of the Groupe Ouest-Est Leucemies Aigues Myeloblastiques. J Clin Oncol. 2000;18:780-787.
27. Marie JP, Huet S, Faussat AM, et al. Multicentric evaluation of the MDR phenotype in leukemia: French Network of the Drug Resistance Intergroup, and Drug Resistance Network of Assistance Publique-Hopitaux de Paris. Leukemia. 1997;11:1086-1094.
28. Campos L, Oriol P, Sabido O, Guyotat D. Simultaneous expression of P-glycoprotein and BCL-2 in acute myeloid leukemia blast cells. Leuk Lymphoma. 1997;27:119-125.
29. de Cremoux P, Tran-Perennou C, Elie C, et al. Quantitation of estradiol receptors alpha and beta and progesterone receptors in human breast tumors by real-time reverse transcription polymerase chain reaction: correlation with protein assay. Biochem Pharmacol. 2002;64:507-515.
30. Beck WT, Mueller TJ, Tanzer LR. Altered surface membrane glycoproteins in Vinca alkaloid-resistant human leukemic lymphoblasts. Cancer Res. 1979;39:2070-2076.
31. + cells. Leuk Res. 1993;17:1031-1035.
32. Lamy T, Drenou B, Grulois I, et al. Multi-drug resistance (MDR) activity in acute leukemia determined by rhodamine 123 efflux assay. Leukemia. 1995;9:1549-1555.
33. van den Heuvel-Eibrink MM, Wiemer EA, de Boevere MJ, et al. MDR1 gene-related clonal selection and P-glycoprotein function and expression in relapsed or refractory acute myeloid leukemia. Blood. 2001;97:3605-3611.
34. List AF, Kopecky KJ, Willman CL, et al. Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. Blood. 2001; 98:3212-3220.
35. Liu Yin JA, Wheatley K, Rees JK, Burnett AK. Comparison of 'sequential' versus 'standard' chemotherapy as re-induction treatment, with or without cyclosporine, in refractory/relapsed acute myeloid leukaemia (AML): results of the UK Medical Research Council AML-R trial. Br J Haematol. 2001;113:713-726.
36. Baer MR, George SL, Dodge RK, et al. Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. Blood. 2002;100:1224-1232.
37. Advani R, Saba HI, Tallman MS, et al. Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar). Blood. 1999;93:787-795.
38. Dorr R, Karanes C, Spier C, et al. Phase I/II study of the P-glycoprotein modulator PSC 833 in patients with acute myeloid leukemia. J Clin Oncol. 2001;19:1589-1599.
39. Solary E, Mannone L, Moreau D, et al. Phase I study of cinchonine, a multidrug resistance reversing agent, combined with the CHVP regimen in relapsed and refractory lymphoproliferative syndromes. Leukemia. 2000;14:2085-2094.
40. Miller TP, Chase EM, Dorr R, Dalton WS, Lam KS, Salmon SE. A phase I/II trial of paclitaxel for non-Hodgkin's lymphoma followed by paclitaxel plus quinine in drug-resistant disease. Anticancer Drugs. 1998;9:135-140.
41. Guerci A, Merlin JL, Missoum N, et al. Predictive value for treatment outcome in acute myeloid leukemia of cellular daunorubicin accumulation and P-glycoprotein expression simultaneously determined by flow cytometry. Blood. 1995;85:2147-2153.
42. Marie JP, Legrand O. MDR1/P-GP expression as a prognostic factor in acute leukemias. Adv Exp Med Biol. 1999;457:1-9.
43. Consoli U, Van NT, Neamati N, et al. Cellular pharmacology of mitoxantrone in p-glycoprotein-positive and -negative human myeloid leukemic cell lines. Leukemia. 1997;11:2066-2074.
44. Belani CP, Doyle LA, Aisner J. Etoposide: current status and future perspectives in the management of malignant neoplasms. Cancer Chemother Pharmacol. 1994;34:S118-S126.
45. Malonne H, Atassi G. DNA topoisomerase targeting drugs: mechanisms of action and perspectives. Anticancer Drugs. 1997;8:811-822.
46. Berman E, McBride M. Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cells. Blood. 1992;79:3267-3273.
47. Ross DD, Doyle LA, Yang W, Tong Y, Cornblatt B. Susceptibility of idarubicin, daunorubicin, and their C-13 alcohol metabolites to transport-mediated multidrug resistance. Biochem Pharmacol. 1995;50:1673-1683.
48. Broxterman HJ, Sonneveld P, van Putten WJ, et al. P-glycoprotein in primary acute myeloid leukemia and treatment outcome of idarubicin/cytosine arabinoside-based induction therapy. Leukemia. 2000;14:1018-1024.
49. Berman E, Heller G, Santorsa J, McKenzie S, et al. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood. 1991;77:1666-1674.
50. Wiernik PH, Banks PL, Case DC Jr, et al. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood. 1992;79:313-319.
51. Cripe LD, Hinton S. Acute myeloid leukemia in adults. Curr Treat Options Oncol. 2000;1:9-17.
52. List AF. Role of multidrug resistance and its pharmacological modulation in acute myeloid leukemia. Leukemia. 1996;10:937-942.
53. Broxterman HJ, Sonneveld P, Feller N, et al. Quality control of multidrug resistance assays in adult acute leukemia: correlation between assays for P-glycoprotein expression and activity. Blood. 1996;87:4809-4816.
54. Beck WT, Grogan TM, Willman CL, et al. Methods to detect P-glycoprotein-associated multidrug resistance in patient tumors: consensus recommendations. Cancer Res. 1996;56:3010-3020.
55. Xie XY, Robb D, Chow S, Hedley DW. Discordant P-glycoprotein antigen expression and transport function in acute myeloid leukemia. Leukemia. 1995;9:1882-1887.
56. Laredo J, Huynh A, Muller C, et al. Effect of the protein kinase C inhibitor staurosporine on chemosensitivity to daunorubicin of normal and leukemic fresh myeloid cells. Blood. 1994;84:229-237.
57. Ferrao P, Sincock P, Cole S, Ashman L. Intracellular P-gp contributes to functional drug efflux and resistance in acute myeloid leukaemia. Leuk Res. 2001;25:395-405.
58. + acute myeloid leukemia cells. Blood. 1993;82:3157-3162.
59. Conde E, Irionda A, Rayan C, et al. Allogeneic bone marrow transplantation versus intensification chemotherapy for acute myelogenous leukaemia in first remission: a prospective controlled trial. Br J Haematol. 1988;68:219-226.
60. Reiffers J, Gaspard MH, Maraninchi D, et al. Comparison of allogeneic or autologous bone marrow transplantation and chemotherapy in patients with acute myeloid leukaemia in first remission: a prospective controlled trial. Br J Haematol. 1989;72:57-63.
61. Harousseau JL, Cahn JY, Pignon B, et al. Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia: The Groupe Ouest Est Leucemies Aigues Myeloblasliques (GOELAM). Blood. 1997;90:2978-2986.
62. Keating S, de Witte T, Suciu S, et al. The influence of HLA-matched sibling donor availability on treatment outcome for patients with AML: an analysis of the AML 8A study of the EORTC Leukaemia Cooperative Group and GIMEMA. European Organization for Research and Treatment of Cancer: Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto. Br J Haematol. 1998;102: 1344-1353.
63. Bloomfield CD, Lawrence D, Byrd JC, et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res. 1998;58:4173-4179.
64. Nguyen S, Leblanc T, Fenaux P, et al. A white blood cell index as the main prognostic factor in t(8;21) acute myeloid leukemia (AML): a survey of 161 cases from the French AML Intergroup. Blood. 2002;99:3517-3523.
65. Schaich M, Harbich-Brutscher E, Pascheberg U, et al. Association of specific cytogenetic aberrations with mdr1 gene expression in adult myeloid leukemia and its implication in treatment outcome. Haematologica. 2002;87:455-464.
66. Borst P, Evers R, Kool M, Wijnholds J. A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst. 2000;92:1295-1302.
67. Solary E, Droin N, Bettaieb A, Corcos L, Dimanche-Boitrel MT, Garrido C. Positive and negative regulation of apoptotic pathways by cytotoxic agents in hematological malignancies. Leukemia. 2000;14:1833-1849.
68. Karp JE. MDR modulation in acute myelogenous leukemia: is it dead? Leukemia. 2001;15: 666-667.